Fintel reports that on January 23, 2025, Barclays downgraded their outlook for Galapagos NV - Depositary Receipt () (NasdaqGS:GLPG) from Equal-Weight to Underweight. Analyst Price Forecast Suggests 48 ...

Barclays downgraded Galapagos (GLPG) to Underweight from Equal Weight with a price target of EUR 22, down from EUR 30. With Galapagos’ ongoing ...

Specifically, Catalent's commercial cell therapy manufacturing facility in Princeton, New Jersey, will support manufacturing ...

Galapagos NV (NASDAQ:GLPG – Get Free Report) has received an average recommendation of “Reduce” from the eight research firms ...

Integral membrane proteins carry out essential functions in the cell, and their activities are often modulated by specific protein-lipid interactions in the membrane. Here, we elucidate the intricate ...

GET MORE AI-GENERATED SIGNALS: January 15, 2025, 11:02 am ET, BY Randall S.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

Jan. 15, 2025 — Scientists have come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. ... New Innovative Local Treatment ...

In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Galapagos (GLPG – Research Report), with a price ...

TD Cowen cut shares of Galapagos (NASDAQ:GLPG – Free Report) from a strong-buy rating to a strong sell rating in a report released on Thursday,Zacks.com reports. Other equities analysts also recently ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...